Journal articleMol Cancer Ther2021
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
- Journal
- Mol Cancer Ther
- Published
- 19 August 2021
- Citations
- 31
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 8
- Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
- Gastrointestinal Cancer P30CA056036↗
- Community Outreach and Engagement P30CA069533↗
- Tissue Core P50CA127297↗
- Targeting Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer R01CA163649↗
- Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer R01CA212600↗
- Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer R01CA216853↗
- Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗